Navigation Links
Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
Date:3/22/2011

PHILADELPHIA Thomas Jefferson University has started recruiting patients for a new National Cancer Institute (NCI)-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer.

Previous laboratory research and population studies have shown that patients taking statins, the class of drugs that lowers cholesterol, had fewer colon polyps, which can lead to cancer if left untreated. However, those findings come largely from retrospective, observational studies originally designed to investigate lipid-lowering or cardiovascular endpoints in the short term rather than tumor endpoints.

"The jury is still out, and we need to get definitive answers," said Bruce Boman, M.D., Ph.D, professor of medical oncology at Thomas Jefferson University and principal investigator for the national clinical trial. "This prospective design comparing a statin against a placebo is what is needed to address the question: Are statins effective chemoprevention agents or not?"

This five-year, nationwide study will be the first randomized, prospective, placebo-controlled, double-blind study to evaluate the drug's role in preventing colon cancer and will involve 1,740 patients in total.

Conducted by a network of cancer research professionals from the National Surgical Adjuvant Breast and Bowel Project (NSABP) at 400 medical centers across North America, including Jefferson, the study involves patients who have recently been diagnosed with early stage colon cancer, and who were not already taking statins for high cholesterol. Those recruited have been surgically treated for stage I and II colon cancers previously.

Patients will be randomly assigned to one of two groups. Each group will take one pill a day for five years. One group will receive rosuvastatin, while the other group will receive a placebo.

The cumulative incidence for developing colorectal adenomas three years after surgery/treatment for early stage colon cancer is 50 percent. Thus, the benefit/risk ratio for chemoprevention intervention is potentially very positive in this high-risk population.

"There will be an estimated 102,900 new cases of colon cancer in the United States this year," said Norman Wolmark, M.D., NSABP's chairman. "In fact, colorectal cancer is the third most common cancer found in men and women in this country. We hope this trial will be an important step in reducing these numbers."

The principal investigator for the trial at Jefferson is Scott Goldstein, M.D, director of the Division of Colon and Rectal Surgery at Thomas Jefferson University.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson surgeon receives outstanding performance award from American College Of Surgeons
2. Jefferson physician named 2010 Emergency Department Director of the Year
3. Jefferson researcher receives 2010 Pancreatic Cancer Action Network-AACR Career Development Award
4. Clue to switch of bladder cancer from locally contained to invasive found by Jefferson scientists
5. Jefferson urologist awarded Lifetime Achievement Award from Endourological Society
6. CancerCare names Jefferson professor Physician of the Year
7. Jefferson study determines bone marrow stromal stem cells may aid in stroke recovery
8. Thomas Jefferson University professor elected AAAS Fellow
9. Stethoscope App gives iPhone New Clinical Skills
10. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
11. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... More than a third of American adults are considered obese, says the ... increased attention in recent years, as an article published May 18th on ... people are familiar with the basic requirements of maintaining a healthy diet and exercise ...
(Date:5/27/2016)... ... 2016 , ... An influential resource amongst nurses and professionals in the health ... the variety of topics detailing why we appreciate nurses in so many different ways. ... gone from being in a major recession to one of the hottest growing professions ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... partnered with Mediaplanet to help educate the many who are unaware of the ... dedicated to aphasia will run within the “Stroke Awareness” campaign. , The link ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year ... medicine. Allison Outerbridge is this year’s Life University winner of a ... the university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter ...
(Date:5/26/2016)... Gilsum, New Hampshire (PRWEB) , ... May 26, 2016 , ... ... natural skin care products, has been honored with a 2016 When Work Works Award ... This prestigious award, part of the national When Work Works project administered by the ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- Niederländische Chirurgen haben eine innovative ... erlaubt, ihre Expertise weltweit zu teilen und so ... mit einer Instant-Messaging-Funktion und der Möglichkeit, in einem ... Afrika, Asien und den USA ... Information und Weiterbildung   "MDLinking ...
(Date:5/24/2016)... HENDERSON, Nev. , May 24, 2016  Diana ... painfully "eats" her organs from the inside out.  This ... her completely dependent on her children and grandchildren to ... of her wheelchair, Diana,s family cannot haul the wheelchair.  ... rides in the car, and Diana is left to ...
(Date:5/24/2016)... May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president ... today. In his new role, Marziani will lead the company,s business development and sales ... improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology: